Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06055816 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Sep 30, 2024 to May 9, 2026 Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Start date changed from estimate of Sep 28, 2023 to Oct 24, 2023
    • Eligibility criteria expanded, about 166 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Trial Details
NCT Number NCT06055816
Lead Sponsor Zhejiang Cancer Hospital
Conditions
(from sponsor)		 Nasopharyngeal Carcinoma
Related terms Nasopharyngeal Carcinoma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov